We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
2008 was a watershed year for stem cell-based treatment, with the first product of this kind going before an FDA review for approval. Learn more from Randal Mills, PhD, chief executive officer of Osiris Therapeutics, as he unveils details of his company’s stem cell-based medicine with host Bruce Japsen. How might the submission of this medicine for FDA approval start us down the path toward an array of stem cell products?
2008 was a watershed year for stem cell-based treatment, with the first product of this kind going before an FDA review for approval. Learn more from Randal Mills, PhD, chief executive officer of Osiris Therapeutics, as he unveils details of his company’s stem cell-based medicine with host Bruce Japsen. How might the submission of this medicine for FDA approval start us down the path toward an array of stem cell products?
Stay current with the best on medical education
